SBPH Spring Bank Pharmaceuticals Inc.

9.6
+0.01  (+0%)
Previous Close 9.59
Open 9.56
Price To Book 2.82
Market Cap 157794192
Shares 16,436,895
Volume 14,575
Short Ratio
Av. Daily Volume 17,911

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data from third cohort met primary endpoint - August 2, 2018. 12 and 24 week data from the final cohort (200mg) due 1H 2019.
Inarigivir - ACHIEVE
Hepatitis B (HBV)
Phase 2 to be initated pending funding.
SB 9200
Respiratory syncytial virus (RSV)
Phase 1/2 trial to be initiated 2H 2019.
SB 11285
Hepatocellular carcinoma
Phase 2 initial data due 2H 2019.
Inarigivir and NUCs
Hepatitis B (HBV)
Phase 2b trial to be initiated 1H 2019 with top-line data due 2020 and 2021.
Inarigivir - (CATALYST 1 and CATALYST 2)
Hepatitis B (HBV)

Latest News

  1. Spring Bank Pharmaceuticals to Participate in Jefferies 2019 HBV Summit
  2. Edited Transcript of SBPH earnings conference call or presentation 11-Mar-19 12:00pm GMT
  3. Spring Bank Pharmaceuticals Reports 2018 Fourth Quarter and Full-Year Financial Results and Corporate Highlights
  4. Spring Bank Pharmaceuticals, Inc. to Host Earnings Call
  5. Spring Bank to Host Conference Call to Discuss Fourth Quarter and Fiscal Year 2018 Results on Monday, March 11
  6. Spring Bank Pharmaceuticals Appoints Atif Abbas, M.D., as Vice President, Head of Oncology & Immunology Clinical Development
  7. Spring Bank Pharmaceuticals Appoints Scott Smith as Chairman of the Board
  8. Spring Bank Pharmaceuticals Hosts R&D Day on Pipeline of Novel Immunomodulatory Therapeutics
  9. Spring Bank Announces Additional Pre-Clinical Data on Its Second-Generation STING Agonist Program at the AACR Special Conference on Tumor Immunology and Immunotherapy
  10. Spring Bank Announces Additional Inarigivir Results at AASLD Conference
  11. Spring Bank Pharmaceuticals, Inc. to Present at Upcoming Healthcare Conferences
  12. Spring Bank Announces Three Poster Presentations on Its Next-Generation STING Agonist Program at the AACR Special Conference on Tumor Immunology and Immunotherapy
  13. Edited Transcript of SBPH earnings conference call or presentation 2-Aug-18 12:00pm GMT